Literature DB >> 15349964

Effect of metal cations on the conformation and inactivation of recombinant human factor VIII.

Tiffany S Derrick1, Ramesh S Kashi, Manzer Durrani, Ashish Jhingan, C Russell Middaugh.   

Abstract

Heavy metals have been implicated in the aggregation of proteins and the pathophysiology of several neurodegenerative diseases. Herein, we describe the interaction of recombinant human factor VIII (rhFVIII) with Al(+3), Tb(+3), Co(+2), and Fe(+3) using a combination of intrinsic fluorescence, circular dichroism, and high-resolution fourth-derivative absorbance analysis. rhFVIII in solution was titrated with the metal cations and the properties of the resulting complexes were examined. rhFVIII has a tendency to aggregate and inactivate slowly over time under physiological conditions, but this aggregation process is greatly accelerated in the presence of metals with Al(+3) being the most efficient. This leads to a complete loss of activity of the protein. Al(+3)-induced conformational changes in the protein were small but detectable with limited changes seen in secondary and tertiary structure. Because rhFVIII is a multidomain protein with subunits linked through divalent metal cations, the small intramolecular changes seen may be attributed to rearrangements of the subunits to an aggregation-competent conformer that is very similar to that of the native form. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15349964     DOI: 10.1002/jps.20167

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  16 in total

1.  Improving the stability of the EC1 domain of E-cadherin by thiol alkylation of the cysteine residue.

Authors:  Maulik Trivedi; Jennifer S Laurence; Todd D Williams; C Russell Middaugh; Teruna J Siahaan
Journal:  Int J Pharm       Date:  2012-04-17       Impact factor: 5.875

2.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

3.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

4.  Aggregation kinetics of recombinant human FVIII (rFVIII).

Authors:  Karthik Ramani; Vivek Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2005-09       Impact factor: 3.534

5.  Domain organization of membrane-bound factor VIII.

Authors:  Svetla Stoilova-McPhie; Gillian C Lynch; Steven Ludtke; B Montgomery Pettitt
Journal:  Biopolymers       Date:  2013-07       Impact factor: 2.505

6.  Canine plasminogen: spectral responses to changes in 6-aminohexanoate and temperature.

Authors:  Jack A Kornblatt; Tanya A Barretto; Ketevan Chigogidze; Bahati Chirwa
Journal:  Anal Chem Insights       Date:  2007-03-22

7.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.

Authors:  Michelle R Simpson-Abelson; Vivek S Purohit; Wing Man Pang; Vandana Iyer; Kunle Odunsi; Todd L Demmy; Sandra J Yokota; Jenni L Loyall; Raymond J Kelleher; Sathy Balu-Iyer; Richard B Bankert
Journal:  Clin Immunol       Date:  2009-04-22       Impact factor: 3.969

8.  Characterization of multiple stable conformers of the EC5 domain of E-cadherin and the interaction of EC5 with E-cadherin peptides.

Authors:  Kai Zheng; Jennifer S Laurence; Krzysztof Kuczera; Gennady Verkhivker; C Russell Middaugh; Teruna J Siahaan
Journal:  Chem Biol Drug Des       Date:  2009-06       Impact factor: 2.817

9.  Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.

Authors:  Karthik Ramani; Razvan D Miclea; Vivek S Purohit; Donald E Mager; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2008-04       Impact factor: 3.534

10.  O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.

Authors:  Razvan D Miclea; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.